Arzerra (ofatumumab) is approved for patients with chronic lymphocytic leukemia (CLL) whose cancer is no longer being controlled by other forms of chemotherapy. The product was approved under the FDA's accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs.
SIGN IN WITH ONE OF YOUR SOCIAL ACCOUNTS
Sign in with your MMM account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH ONE OF YOUR SOCIAL ACCOUNTS
REGISTER FOR FREE WITH A MMM ACCOUNT
Enter your MMM registration email address to receive a password reset link.
ENTER NEW PASSWORD
It looks like we already have a MMM account for:
Please confirm the information BELOW to link this account to your account
I would like to receive relevant information via email from Haymarket Media.
Not you? Create an account for free »